To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

ACL Reconstruction: increased patellar tendon donor site healing with Platelet-Rich Plasma

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
May 2013

ACL Reconstruction: increased patellar tendon donor site healing with Platelet-Rich Plasma

Vol: 2| Issue: 4| Number:22| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Patellar Tendon Healing With Platelet-Rich Plasma : A Prospective Randomized Controlled Trial

Am J Sports Med. 2012 Jun;40(6):1282-8. doi: 10.1177/0363546512441344. Epub 2012 Apr 2

Contributing Authors:
AM de Almeida MK Demange MF Sobrado MB Rodrigues A Pedrinelli AJ Hernandez

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

27 patients with anterior cruciate ligament (ACL) injuries were randomized to receive ACL reconstruction with or without platelet rich plasma (PRP) in the patellar tendon harvest site. At 6 months, the PRP group had a significantly smaller patellar tendon gap area than the control group as measured on MRI. The PRP group also experienced less pain than the control group immediately after surgery.Th...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue